⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth
businesswire.com
JNJ
GMAB
Tissue Factor-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality
globenewswire.com
PFE
GMAB
IMP Labeling Workflows That Reduce Relabeling Risk and Start-Up Delays, Upcoming Webinar Hosted by Xtalks
prnewswire.com
JAZZ
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com
GMAB
Major Shareholder Announcement
globenewswire.com
GMAB
Genmab Announces Financial Results for the First Quarter of 2026
globenewswire.com
GMAB
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development Platforms
globenewswire.com
AMGN
AZN
GMAB
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
globenewswire.com
JNJ
AMGN
GMAB
ABBV
AZN
PFE
BMY
REGN
XNCR
ZYME
Genmab A/S Share Capital Reduction
globenewswire.com
GMAB
Major Shareholder Announcement
globenewswire.com
GMAB